Small molecule and peptide therapies for chronic heart failure: a patent review (2011 – 2014)

Bibliography

• Morrissey RP, Czer L, Shah PK. Chronic heart failure: current evidence, challenges to therapy, and future directions. Am J Cardiovasc Drugs 2011;11(3):153-71
   PubMed Web of Science ®Google Scholar
• Braunwald E. Heart failure. JACC Heart Fail 2013;1(1):1-20
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013;6(3):606-19
   PubMed Web of Science ®Google Scholar
• Roenicke V, Leclair S, Hoffmann A, et al. Emerging therapeutic targets in chronic heart failure: part II. Expert Opin Ther Targets 2003;7(1):49-59
   PubMed Web of Science ®Google Scholar
• Anker SD, Jankowska EA, Okonko DO. Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002. Expert Opin Ther Pat 2004;14(5):639-54
   Web of Science ®Google Scholar
• Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251(2):471-6
   PubMed Web of Science ®Google Scholar
• Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005;107(2):198-211
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001;99(2-3):87-92
   PubMed Web of Science ®Google Scholar
• Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91(5):434-40
   PubMed Web of Science ®Google Scholar
• Scott JD, Santana LF. A-kinase anchoring proteins: getting to the heart of the matter. Circulation 2010;121(10):1264-71
   PubMed Web of Science ®Google Scholar
• Yuan Y, Tang Q. GW25-e3232 IRAK4 deficiency promotes cardiac remodeling. J Am Coll Cardiol 2014;64(16 Suppl):C13
   PubMedGoogle Scholar
• Maekawa Y, Mizue N, Chan A, et al. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation 2009;120(14):1401-14
   PubMed Web of Science ®Google Scholar
• Sawyer DB, Caggiano A. Neuregulin-1beta for the treatment of systolic heart failure. J Mol Cell Cardiol 2011;51(4):501-5
   PubMed Web of Science ®Google Scholar
• Geisberg CA, Lenihan DJ. Neuregulin in heart failure : reverse translation from cancer cardiotoxicity to new heart failure therapy. Herz 2011;36(4):306-10
   PubMed Web of Science ®Google Scholar
• Brittain E, Muldowney J, Geisberg C, et al. Evaluation of cardiac function in symptomatic heart failure patients in a single infusion, phase 1, dose escalation study of glial growth factor 2. J Am Coll Cardiol 2013;61(10 Suppl):E715
   Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370(15):1383-92
   PubMed Web of Science ®Google Scholar
• Fillmore N, Lopaschuk GD. Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim Biophys Acta 2013;1833(4):857-65
   PubMed Web of Science ®Google Scholar
• Piao L, Sidhu VK, Fang Y-H, et al. Chronic inhibition of pyruvate dehydrogenase kinase with dichloroacetate improves cardiac metabolism and function in right ventricular hypertrophy in fawn-hooded rats. J Am Coll Cardiol 2012;59(13 Suppl):E1604
   PubMed Web of Science ®Google Scholar
• Li J, Kritzer MD, Michel JJ, et al. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ Res 2013;112(1):128-39
   PubMed Web of Science ®Google Scholar
• Passariello CL, Gayanilo M, Kritzer MD, et al. p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in alpha-tropomyosin Glu180Gly transgenic mice. Am J Physiol Heart Circ Physiol 2013;305(7):H1010-19
   PubMed Web of Science ®Google Scholar
• Schulz EM, Dixon AE, Burhans MS, et al. Abstract 315: The role of mixed lineage kinase 3 in inflammatory cell-fibroblast communication. Circ Res 2014;115(Suppl 1):A315
   Google Scholar
• Lal H, Ahmad F, Parikh S, et al. Troponin I-interacting protein kinase: a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. Circ J 2014;78(7):1514-19
   PubMed Web of Science ®Google Scholar
• Wang X, Wang J, Su M, et al. TNNI3K, a cardiac-specific kinase, promotes physiological cardiac hypertrophy in transgenic mice. PLoS One 2013;8(3):e58570
   PubMedGoogle Scholar
• Jaaskelainen P, Miettinen R, Karkkainen P, et al. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. Ann Med 2004;36(1):23-32
   PubMed Web of Science ®Google Scholar
• Starr R, Offer G. The interaction of C-protein with heavy meromyosin and subfragment-2. Biochem J 1978;171(3):813-16
   PubMed Web of Science ®Google Scholar
• Vikstrom KL, Leinwand LA. Contractile protein mutations and heart disease. Curr Opin Cell Biol 1996;8(1):97-105
   PubMed Web of Science ®Google Scholar
• Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 1997;49(1):1-51
   PubMed Web of Science ®Google Scholar
• Pessah IN, Stambuk RA, Casida JE. Ca2+-activated ryanodine binding: mechanisms of sensitivity and intensity modulation by Mg2+, caffeine, and adenine nucleotides. Mol Pharm 1987;31(3):232-8
   Web of Science ®Google Scholar
• Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 1983;245(1):C1-14
   PubMed Web of Science ®Google Scholar
• Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (Ryanodine Receptor): defective regulation in failing hearts. Cell 2000;101(4):365-76
   PubMed Web of Science ®Google Scholar
• Zhang L, Kelley J, Schmeisser G, et al. Complex Formation between Junctin, Triadin, Calsequestrin, and the Ryanodine Receptor: Proteins of the Cardiac Junctional Sarcoplasmic Reticulum Membrane. J Biol Chem 1997;272(37):23389-97
   PubMed Web of Science ®Google Scholar
• Ortlepp JR, Vesper K, Mevissen V, et al. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med 2003;81(6):363-7
   PubMed Web of Science ®Google Scholar
• Struthers M, Pasternak A. CCR2 antagonists. Curr Top Med Chem 2010;10(13):1278-98
   PubMed Web of Science ®Google Scholar
• Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Pat 2009;19(3):295-303
   PubMed Web of Science ®Google Scholar
• Loh YP, Koshimizu H, Cawley NX, et al. Serpinins: role in granule biogenesis, inhibition of cell death and cardiac function. Curr Med Chem 2012;19(24):4086-92
   PubMed Web of Science ®Google Scholar
• Koshimizu H, Cawley NX, Yergy AL, et al. Role of pGlu-serpinin, a novel chromogranin A-derived peptide in inhibition of cell death. J Mol Neurosci 2011;45(2):294-303
   PubMed Web of Science ®Google Scholar
• Feldman AM, Cheksis-Feiner E, Hamad E, et al. Adenosine receptor subtypes and the heart failure phenotype: translating lessons from mice to man. Trans Am Clin Climatol Assoc 2011;122:198-214
   PubMedGoogle Scholar
• Asakura M, Asanuma H, Kim J, et al. Impact of adenosine receptor signaling and metabolism on pathophysiology in patients with chronic heart failure. Hypertens Res 2007;30(9):781-7
   PubMed Web of Science ®Google Scholar
• Headrick JP, Ashton KJ, Rose’meyer RB, et al. Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacol Ther 2013;140(1):92-111
   PubMed Web of Science ®Google Scholar
• Buys E, Sips P. New insights into the role of soluble guanylate cyclase in blood pressure regulation. Curr Opin Nephrol Hypertens 2014;23(2):135-42
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 2013;18(2):123-34
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317(13):799-804
   PubMed Web of Science ®Google Scholar
• Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123(20):2263-73
   PubMed Web of Science ®Google Scholar
• Follmann M, Griebenow N, Hahn MG, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 2013;52(36):9442-62
   PubMed Web of Science ®Google Scholar
• Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2011: cardiovascular drugs. Expert Opin Investig Drugs 2012;21(10):1449-62
   PubMed Web of Science ®Google Scholar
• Gerassimou C, Kotanidou A, Zhou Z, et al. Regulation of the expression of soluble guanylyl cyclase by reactive oxygen species. Br J Pharmacol 2007;150(8):1084-91
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Jovanovic A, Lehinant S. Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep 2011;8(1):38-44
   PubMedGoogle Scholar
• Priviero FB, Webb RC. Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol 2010;56(3):229-33
   PubMed Web of Science ®Google Scholar
• Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007;49(5):1128-33
   PubMed Web of Science ®Google Scholar
• Tamargo J, Duarte J, Caballero R, et al. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. Curr Opin Investig Drugs 2010;11(9):1039-47
   PubMed Web of Science ®Google Scholar
• Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101(5):558-69
   PubMed Web of Science ®Google Scholar
• Frishman WH. Beta-Adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther 2013;18(4):310-19
   PubMed Web of Science ®Google Scholar
• Di Franco A, Sarullo FM, Salerno Y, et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs 2014;14(2):101-10
   PubMed Web of Science ®Google Scholar
• Bryson CL, Smith NL, Kuller LH, et al. Risk of congestive heart failure in an elderly population treated with peripheral alpha-1 antagonists. J Am Geriatr Soc 2004;52(10):1648-54
   PubMed Web of Science ®Google Scholar
• Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999;99(13):1685-91
   PubMed Web of Science ®Google Scholar
• Newby LK, Marber MS, Melloni C, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 2014;384(9949):1187-95
   PubMed Web of Science ®Google Scholar
• Streicher JM, Ren S, Herschman H, et al. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res 2010;106(8):1434-43
   PubMed Web of Science ®Google Scholar
• Asrih M, Mach F, Nencioni A, et al. Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. Mediators Inflamm 2013;2013:367245
   PubMedGoogle Scholar
• A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy. Available from: https://clinicaltrials.gov/ct2/show/NCT02057341 [Last accessed 16 March 2015]
   Google Scholar
• Semigran MJ. Type 5 phosphodiesterase inhibition: the focus shifts to the heart. Circulation 2005;112(17):2589-91
   PubMed Web of Science ®Google Scholar
• Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50(22):2136-44
   PubMed Web of Science ®Google Scholar
• Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116(14):1555-62
   PubMed Web of Science ®Google Scholar
• Guazzi M, Arena R, Pinkstaff S, et al. Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol 2009;136(3):341-3
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013;309(12):1268-77
   PubMed Web of Science ®Google Scholar
• Miller CL, Oikawa M, Cai Y, et al. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 2009;105(10):956-64
   PubMed Web of Science ®Google Scholar
• Ono K, Iijima T. Cardiac T-type Ca(2+) channels in the heart. J Mol Cell Cardiol 2010;48(1):65-70
   PubMed Web of Science ®Google Scholar
• Clozel JP, Ertel EA, Ertel SI. Voltage-gated T-type Ca2+ channels and heart failure. Proc Assoc Am Physicians 1999;111(5):429-37
   PubMedGoogle Scholar
• Tjeerdsma G, Brouwer J, de Kam PJ, et al. Effect of mibefradil on heart rate variability in patients with chronic heart failure. Int J Cardiol 2000;73(1):55-60
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Knerr L, Wallberg A. T-type calcium channels inhibitors: a patent review. Expert Opin Ther Pat 2011;21(1):85-101
   PubMed Web of Science ®Google Scholar
• Yang ZQ, Schlegel KA, Shu Y, et al. Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett 2010;1(9):504-9
   PubMed Web of Science ®Google Scholar
• Konhilas JP, Leinwand LA. The effects of biological sex and diet on the development of heart failure. Circulation 2007;116(23):2747-59
   PubMed Web of Science ®Google Scholar
• Pelzer T, Loza PA, Hu K, et al. Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation 2005;111(12):1492-8
   PubMed Web of Science ®Google Scholar
• Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol 2012;86(10):1491-504
   PubMed Web of Science ®Google Scholar
• Schmidt M, Dekker FJ, Maarsingh H. Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol Rev 2013;65(2):670-709
   PubMed Web of Science ®Google Scholar
• Pereira L, Cheng H, Lao DH, et al. Epac2 mediates cardiac beta1-adrenergic-dependent sarcoplasmic reticulum Ca2+ leak and arrhythmia. Circulation 2013;127(8):913-22
   PubMed Web of Science ®Google Scholar
• Lavoie JL, Sigmund CD. Minireview:overview of the renin-angiotensin system–an endocrine and paracrine system. Endocrinology 2003;144(6):2179-83
   PubMed Web of Science ®Google Scholar
• Valluri A, Struthers AD, Lang CC. Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure. Curr Heart Fail Rep 2014;11(1):31-9
   PubMedGoogle Scholar
• Szelke M, Leckie B, Hallett A, et al. Potent new inhibitors of human renin. Nature 1982;299(5883):555-7
   PubMed Web of Science ®Google Scholar
• Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7(5):399-410
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure (ATMOSPHERE). Available from: https://www.clinicaltrials.gov/ct2/show/NCT00853658 [Last accessed 15 March 2015]
   Google Scholar
• Yokokawa F. Recent progress on the discovery of non-peptidic direct renin inhibitors for the clinical management of hypertension. Expert Opin Drug Discov 2013;8(6):673-90
   PubMed Web of Science ®Google Scholar
• Yahiro E, Miura S, Imaizumi S, et al. Chymase inhibitors. Curr Pharm Des 2013;19(17):3065-71
   PubMed Web of Science ®Google Scholar
• McKinney CA, Fattah C, Loughrey CM, et al. Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin Sci 2014;126(12):815-27
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87(5):E1-9
   PubMed Web of Science ®Google Scholar
• Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 2014;11(7):413-26
   PubMed Web of Science ®Google Scholar
• Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 2010;55(1):90-8
   PubMed Web of Science ®Google Scholar
• Chamsi-Pasha MA, Shao Z, Tang WH. Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep 2014;11(1):58-63
   PubMedGoogle Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103(6):904-12
   PubMed Web of Science ®Google Scholar
• Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013;65(2):809-48
   PubMed Web of Science ®Google Scholar
• Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005;45(5):840-4
   PubMed Web of Science ®Google Scholar
• Matavelli LC, Siragy HM. AT2 receptor activities and pathophysiological implications. J Cardiovasc Pharmacol 2015;65(3):226-32
   PubMed Web of Science ®Google Scholar
• Whitebread S, Mele M, Kamber B, et al. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989;163(1):284-91
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Rompe F, Kaschina E, et al. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst 2010;11(1):67-73
   PubMed Web of Science ®Google Scholar
• Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004;47(24):5995-6008
   PubMed Web of Science ®Google Scholar
• Sumners C, de Kloet AD, Krause EG, et al. Angiotensin type 2 receptors: blood pressure regulation and end organ damage. Curr Opin Pharmacol 2015;21C:115-21
   Google Scholar
• Suzuki T, Yamazaki T, Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 2001;51(3):489-94
   PubMed Web of Science ®Google Scholar
• Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10(7):607-13
   PubMed Web of Science ®Google Scholar
• von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014;144(1):41-9
   PubMed Web of Science ®Google Scholar
• Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 2013;94(4):445-8
   PubMed Web of Science ®Google Scholar
• Schreuder HA, Liesum A, Kroll K, et al. Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases. Biochem Biophys Res Commun 2014;445(2):451-6
   PubMed Web of Science ®Google Scholar
• Ocaranza MP, Michea L, Chiong M, et al. Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. Clin Sci 2014;127(9):549-57
   PubMed Web of Science ®Google Scholar
• Ruf S, Buning C, Schreuder H, et al. Inhibition of CatA: an emerging strategy for the treatment of heart failure. Future Med Chem 2013;5(4):399-409
   PubMed Web of Science ®Google Scholar
• Sanofi. Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases. US20130123325; 2013
   Google Scholar
• Sanofi. Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases. US20130123276; 2013
   Google Scholar
• Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 2006;24(3-4):239-46
   PubMedGoogle Scholar
• Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 2007;50(4):596-9
   PubMed Web of Science ®Google Scholar
• Savergnini SQ, Ianzer D, Carvalho MB, et al. The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. PLoS One 2013;8(3):e57757
   PubMedGoogle Scholar
• Zhang T, Li Z, Dang H, et al. Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol 2012;302(1):H299-311
   PubMed Web of Science ®Google Scholar
• Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant 2013;28(1):36-43
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Schiffrin EL. Role of Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. Circ Res 2015;116(1):206-13
   PubMed Web of Science ®Google Scholar
• Richards AM. Mineralocorticoid receptor antagonists for heart failure. Expert Opin Pharmacother 2011;12(18):2801-15
   PubMed Web of Science ®Google Scholar
• Pitt B. Heart failure: the role for mineralocorticoid receptor antagonists. Swiss Med Wkly 2014;144:w13959
   PubMed Web of Science ®Google Scholar
• Leftheris K, Zheng Y, Lala DS. Chapter 6 - recent advances in mineralocorticoid receptor antagonists. In: Macor JE, editor. Annual Reports in Medicinal Chemistry. Academic Press, Waltham, MA; 2011. 89-102
   Google Scholar
• Kolkhof P, Delbeck M, Kretschmer A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014;64(1):69-78
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 2011;57(2):131-40
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365(1):32-43
   PubMed Web of Science ®Google Scholar
• Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS ONE 2013;8(3):e58287
   PubMed Web of Science ®Google Scholar
• Dunkel P, Gelain A, Barlocco D, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target. Curr Med Chem 2008;15(18):1827-39
   PubMed Web of Science ®Google Scholar
• Boomsma F, de Kam PJ, Tjeerdsma G, et al. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J 2000;21(22):1859-63
   PubMed Web of Science ®Google Scholar
• Dunkel P, Balogh B, Meleddu R, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1: a patent survey. Expert Opin Ther Pat 2011;21(9):1453-71
   PubMed Web of Science ®Google Scholar
• Kalra A, Maharaj V, Goldsmith SR. Vasopressin receptor antagonists: from pivotal trials to current practice. Curr Heart Fail Rep 2014;11(1):10-18
   PubMedGoogle Scholar
• Konstam MA, Gheorghiade M, Burnett JCJr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297(12):1319-31
   PubMed Web of Science ®Google Scholar
• Lanfear DE, Sabbah HN, Goldsmith SR, et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail 2013;6(1):47-52
   PubMed Web of Science ®Google Scholar
• Hauptman PJ, Burnett J, Gheorghiade M, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013;19(6):390-7
   PubMed Web of Science ®Google Scholar
• Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013;61(2):169-74
   PubMed Web of Science ®Google Scholar
• Nielsen S, Chou CL, Marples D, et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 1995;92(4):1013-17
   PubMed Web of Science ®Google Scholar
• Ong KL, Lam KS, Cheung BM. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 2005;19(1):65-75
   PubMed Web of Science ®Google Scholar
• Tsoukas P, Kane E, Giaid A. Potential Clinical Implications of the Urotensin II Receptor Antagonists. Front Pharmacol 2011;2:38
   Google Scholar
• Carotenuto A, Grieco P, Rovero P, et al. Urotensin-II receptor antagonists. Curr Med Chem 2006;13(3):267-75
   PubMed Web of Science ®Google Scholar
• Welling PA, Ho K. A comprehensive guide to the ROMK potassium channel: form and function in health and disease. Am J Physiol Renal Physiol 2009;297(4):F849-63
   PubMed Web of Science ®Google Scholar
• Garcia ML, Kaczorowski GJ. Targeting the inward-rectifier potassium channel ROMK in cardiovascular disease. Curr Opin Pharmacol 2014;15:1-6
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993-1004
   PubMed Web of Science ®Google Scholar
• Simoes e Silva AC, Silveira KD, Ferreira AJ, et al. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013;169(3):477-92
   PubMed Web of Science ®Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34(31):2453-63
   PubMed Web of Science ®Google Scholar
• Trinh J, Palmer K. Inotropes. Anaesthes Intens Care Med 2012;13(10):492-8
   Google Scholar
• Phase IIb safety and efficacy study of four dose regimens of BAY1021189 in patients with heart failure with reduced ejection fraction suffering from worsening chronic heart failure (SOCRATES-REDUCED). Available from: https://clinicaltrials.gov/ct2/show/NCT01951625 [Last accessed 15 March 2015]
   Google Scholar
• Evaluation of the effects of 4 oral dosages of S 44121 versus placebo on cardiac function and NT-proBNP in patients with chronic heart failure and left ventricular dysfunction not treated with a beta-blocker. A 12-week, randomized, double-blind, parallel-group, placebo controlled, international multicentre study. Available from: http://adisinsight.springer.com/trials/700201444 [Last accessed 15 March 2015]
   Google Scholar
• Cleland JGF, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011;378(9792):676-83
   PubMed Web of Science ®Google Scholar
• Greenberg BH, Chou W, Saikali KG, et al. Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina. JACC: Heart Failure 2015;3(1):22-9
   PubMed Web of Science ®Google Scholar
• Cytokinetics, incorporated reports fourth quarter 2014 financial results. Available from: http://www.nasdaq.com/press-release/cytokinetics-incorporated-reports-fourth-quarter-2014-financial-results-20150212-01175#ixzz3UVXV7FvY [Last accessed 15 March 2015]
   Google Scholar
• Morrone D, Marzilli M. Role of RAAS inhibition in preventing left ventricular remodeling in patients post myocardial infarction. Heart Metab 2010;47:9-13
   Google Scholar
• A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01944683 [Last accessed 15 March 2015]
   Google Scholar
• Xu Y, Li X, Liu X, et al. Neuregulin-1/ErbB signaling and chronic heart failure. In: Paul MV, editor. Advances in pharmacology. Academic Press, Waltham, MA; 2010. p. 31-51
   Google Scholar